PHAT Phathom Pharmaceuticals Inc
Price (delayed)
$5.49
Market cap
$382.31M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.29
Enterprise value
$617.35M
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States,
Highlights
Phathom Pharmaceuticals's gross profit has soared by 115% from the previous quarter
The revenue has soared by 110% from the previous quarter
The EPS has declined by 35% year-on-year but it is up by 8% since the previous quarter
PHAT's net income has dropped by 66% year-on-year
The quick ratio has dropped by 60% year-on-year and by 28% since the previous quarter
Key stats
What are the main financial stats of PHAT
Market
Valuations
Earnings
Shares outstanding
69.64M
Market cap
$382.31M
Enterprise value
$617.35M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
6.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.17
Revenue
$55.25M
Gross profit
$47.28M
Operating income
-$277.47M
Net income
-$334.33M
EBIT
-$262.32M
EBITDA
-$261.52M
Free cash flow
-$266.91M
Per share
Balance sheet
Liquidity
EPS
-$5.29
EPS diluted
-$5.29
Free cash flow per share
-$4.22
Book value per share
-$3.71
Revenue per share
$0.87
TBVPS
$5.99
Total assets
$378.32M
Total liabilities
$631.9M
Debt
$535.17M
Equity
-$253.58M
Working capital
$274.41M
Debt to equity
-2.11
Current ratio
4.2
Quick ratio
3.95
Net debt/EBITDA
-0.9
Margins
Efficiency
Dividend
EBITDA margin
-473.3%
Gross margin
85.6%
Net margin
-605.1%
Operating margin
-502.2%
Return on assets
-92.8%
Return on equity
N/A
Return on invested capital
-54.1%
Return on capital employed
-89.7%
Return on sales
-474.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PHAT stock price
How has the Phathom Pharmaceuticals stock price performed over time
Intraday
7.23%
1 week
-14.49%
1 month
-0.54%
1 year
-43.98%
YTD
-32.39%
QTD
-12.44%
Financial performance
How have Phathom Pharmaceuticals's revenue and profit performed over time
Revenue
$55.25M
Gross profit
$47.28M
Operating income
-$277.47M
Net income
-$334.33M
Gross margin
85.6%
Net margin
-605.1%
Phathom Pharmaceuticals's gross profit has soared by 115% from the previous quarter
The revenue has soared by 110% from the previous quarter
The operating margin has soared by 98% year-on-year and by 54% since the previous quarter
PHAT's net margin has surged by 98% year-on-year and by 53% since the previous quarter
Growth
What is Phathom Pharmaceuticals's growth rate over time
Valuation
What is Phathom Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
6.28
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.17
The EPS has declined by 35% year-on-year but it is up by 8% since the previous quarter
The equity fell by 36% QoQ
The revenue has soared by 110% from the previous quarter
The price to sales (P/S) is 93% lower than the last 4 quarters average of 88.4
Efficiency
How efficient is Phathom Pharmaceuticals business performance
The ROS has soared by 98% year-on-year and by 54% since the previous quarter
Phathom Pharmaceuticals's ROA has decreased by 22% YoY
The ROIC has grown by 9% from the previous quarter and by 9% YoY
Dividends
What is PHAT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PHAT.
Financial health
How did Phathom Pharmaceuticals financials performed over time
The total assets is 40% smaller than the total liabilities
The quick ratio has dropped by 60% year-on-year and by 28% since the previous quarter
The current ratio has plunged by 59% YoY and by 27% from the previous quarter
The debt to equity has surged by 65% year-on-year and by 21% since the previous quarter
The equity fell by 36% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.